Qure.ai Recognized Among TIME's 100 Most Influential Companies of 2025
NEW YORK--(BUSINESS WIRE)--Qure.ai, the world's most widely adopted digital health innovator, has been named to TIME's 2025 TIME100 Most Influential Companies list. Now in its fifth year, the TIME100 list highlights companies making an extraordinary global impact through innovation, ambition, and measurable success.
TIME's editorial spotlighted Qure.ai's work in advancing diagnostic equity through AI, stating: 'Trained on one of the world's largest data sets, Qure.ai's algorithms are as accurate as a radiologist, according to the company, providing crucial insights in rural or developing areas where specialists may not be available. Qure.ai tools have now been deployed in more than 100 countries, and the company has 18 FDA clearances—the greatest number for lung cancer AI in the U.S.—including three new approvals in 2024.'
Qure.ai was selected alongside iconic and dynamic brands such as Abbott, Midi Health, Vertex Pharmaceuticals, Function Health, Gilead, CRISPR Therapeutics, NBBJ, and Northwell Health, and is featured in the Pioneer category among health tech AI firms on the 2025 list.
Speaking on the recognition, Prashant Warier, CEO and Founder said, 'To be named among TIME's 100 Most Influential Companies is an acknowledgment of a simple but urgent belief: that access to timely, high-quality diagnostics should not depend on where you live. This honor reflects the dedication of our teams and partners across continents, working to close the gap between innovation and impact. This recognition pushes us to keep advancing that future, where care begins long before crisis.'
This milestone recognition follows a pivotal year for Qure.ai, marked by accelerated momentum in the United States. With over 18 FDA-cleared findings and the launch of its Lung Cancer Care Continuum, a portfolio of AI solutions to detect, measure, and manage lung nodules; Qure.ai now offers an end-to-end suite that supports earlier lung cancer diagnosis across diverse care settings. Backed by a strategic Series D round led by global investors including Lightspeed, 360 One Asset, and the Merck Global Health Innovation Fund, the company is scaling its commercial and clinical impact worldwide.
On the global front, Qure.ai continues to lead in innovation for low- and middle-income countries, drawing on its deep experience in TB surveillance at scale. Its newest offering, Aira, a multi-disease clinical AI co-pilot, was launched at the World Health Assembly in Geneva to support care coordination in resource-constrained settings.
To compile this year's TIME100 list, TIME's editors evaluated nominees across sectors based on impact, innovation, ambition, and success, after polling its global network of journalists and outside experts. The final list spotlights 105 companies helping chart a path forward for the world.
See the full list here:
About Qure.ai
Qure.ai is a health tech company that uses deep learning and Artificial Intelligence (AI) to make healthcare more accessible and equitable for patients worldwide. Our solutions power the efficient identification and management of Tuberculosis (TB), Lung Cancer and Neurocritical conditions to support clinicians and propel developments in the pharmaceutical and medical device industries. We empower healthcare by helping to identify conditions fast, prioritize treatment planning and ultimately improve quality of patient life.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Magazine
37 minutes ago
- Time Magazine
China's Relationship With the World After the Israel-Iran War
Donald Trump's leadership style, at once volatile and commanding, could be both an obstacle and an opportunity for Beijing. There might be no better example than the recent events involving the Middle East: After nearly two weeks of traded attacks between Israel and Iran, the President made the controversial decision to authorize U.S. strikes on three Iranian nuclear facilities, risking prolonged American involvement in yet another unpopular war in the Middle East. Then just two days later, Trump announced that he had brokered a ceasefire between Israel and Iran—one that almost collapsed but then appeared to hold as Trump let off an expletive-filled rant against both countries, warning Israel not to drop more bombs. Trump even boasted of the benefits his truce would bring to other countries. 'China can now continue to purchase Oil from Iran,' Trump posted on Truth Social on Tuesday. 'Hopefully, they will be purchasing plenty from the U.S., also. It was my Great Honor to make this happen!' Trump's comments came after Secretary of State Marco Rubio said on Fox News on Sunday that he had encouraged China to advise Iran not to close the Strait of Hormuz—the narrow waterway through which much of the world's oil trade flows through and which Iran had threatened to close in response to U.S. intervention. China relies on crude oil imports from the Middle East, particularly Saudi Arabia, which pass through the strait, but is also the largest importer of Iranian oil, which is under economic sanctions by the U.S. Reports suggested that Trump's post indicated possible sanctions relief, but the White House later clarified to media outlets: 'The president was simply calling attention to the fact that, because of his decisive actions to obliterate Iran's nuclear facilities and broker a ceasefire between Israel and Iran, the Strait of Hormuz will not be impacted, which would have been devastating for China.' China, unlike the U.S. with Israel, made no indication that it would step in to militarily assist its longtime friend Iran. Instead, the Asian nation, which has in recent years tried to position itself as a global peacebroker, made fervent calls for deescalation, verbal condemnations of Israel's attacks, and urged the U.S. not to get involved. Ultimately, though, China's offers to mediate were not taken up, and instead it was—at least according to himself—Trump's strongman stance that managed to bring an end for now to the hostilities between Israel and Iran. But experts tell TIME it was no surprise to anyone, including China, that only the U.S. could have brought an end to the war. 'It is not surprising that Israel signs a cease-fire when the United States applies real pressure, because they could not pursue any conflict, in Iran or in Gaza, without the continual supply of weapons, ammunition, and military tech from the United States,' says William Figueroa, an assistant professor of international relations at the University of Groningen. 'When the person signing the checks says they really mean it, you listen.' While China has deepened its investment in the Middle East over the years and developed close economic ties with Iran while maintaining ties with Israel, it does not hold the same level of either economic or political leverage over either country as the U.S. 'Iran sees China more as an economic partner than a security ally,' Lin Jing, a research fellow at the Middle East Institute at the National University of Singapore, tells TIME. China has also offered sharp criticisms of Israel's bombardment of Gaza, and of its attacks on Iran, which would have made it unlikely for Israel to accept it as a mediator. China seemed to know this, Figueroa says, and was instead pushing the U.S. to exert its influence over Israel to end the war. Still, experts say, China will learn from how the war and its ceasefire played out, if only to reinforce its view of the U.S. as an unpredictable power. And Rubio will meet next week with foreign ministers from Australia, India, and Japan to build on 'momentum to advance a free, open, and secure Indo-Pacific'—language that suggests the U.S. wants to return focus to countering the regional threat from China. Strikes reinforce Chinese view of U.S. instability China already saw the U.S. under the Trump Administration as an unstable partner, particularly after Trump slammed the world with staggering tariff rates before abruptly reversing course. Trump's tariffs 'were accelerating a trend of Chinese businesses looking more and more overseas,' Figueroa says. China exports heavily to U.S. markets, and Trump's tariffs on China—which rose to a prohibitive 145% before being temporarily lowered to 30%—left many Chinese and American businesses in a state of uncertainty. Chinese President Xi Jinping has made attempts to strengthen trade relations with other countries in recent months, assuring the world of its stability as a trading partner in contrast with the U.S. In a meeting with Singaporean Prime Minister Lawrence Wong this week, Xi pointed to 'the current complex and turbulent international situation' to emphasize the need for closer ties. The Middle East too has become an important market and site of diplomacy for China. Figueroa says U.S. backing of Israel 'will only intensify the trend of China leaning towards the Arab states and linking regional instability to the United States and Israel.' That the U.S. intervened to strike Iranian nuclear facilities, potentially upending decades of global nuclear diplomacy, 'reinforces [China's] view of the U.S. as a disruptive power, intent on setting rules, but not following them when inconvenient,' Lin says. Isaac Kardon, a senior fellow for China studies at the Carnegie Endowment for International Peace, told the South China Morning Post that the U.S. strikes on Iran might ring alarm bells for China. American escalation showed China that 'massive use of force actually is 'on the table' and may be employed very quickly and even impulsively by a leader who is showing himself to be less gun-shy and more risk-acceptant than his first term,' Kardon said. China's approach to the Israel-Iran war showed that it wanted to 'avoid direct confrontation with the U.S.,' Lin, the Singapore-based researcher, adds. While China urged 'countries with special influence on Israel' not to fan the flames of the war, it did not explicitly name the U.S. But having seen that the U.S. is willing to engage militarily, China may recalculate its own foreign policy approach, including over Taiwan, Lin says. 'China may also look a bit more skeptically at Trump's efforts to negotiate, having seen where negotiations got Iran,' Figueroa says. At the same time, Lin says protracted U.S. involvement in the Middle East, which may result as the U.S. aims to enforce the ceasefire between Tehran and Tel Aviv while reentering diplomatic talks with Iran and pushing Israel to end its war in Gaza, could advantage China 'by drawing its attention away from Asia.' 'U.S. power is finite—political bandwidth and strategic bandwidth is also limited,' Mohammed Alsudairi, an international relations lecturer at the Australian National University, told the Washington Post. 'The U.S. could be dragged into a quagmire, not of its own making.' And Beijing would support such a quagmire, Kardon told SCMP, as it would 'keep U.S. naval and air forces tied up in Western Asia instead of in the Western Pacific where China's strategic attention is concentrated.' Uncertainty around Taiwan Tensions around Taiwan have been on the rise in recent years. Beijing views Taiwan as part of China and has stepped up political and military pressure towards its reunification with mainland China. A majority of countries do not recognize Taiwan as an independent country, including the U.S., although the U.S. opposes the use of force by Beijing to claim Taiwan and provides Taiwan with defensive military capabilities. Taiwan's Defense Minister Wellington Koo said Thursday that the island is determined to defend itself, after outlining annual military exercises for July. The defense ministry reported earlier that day another Chinese 'joint combat readiness patrol' around Taiwan, involving warships and warplanes. China previously sent 46 military aircraft over the Taiwan Strait in the 24 hours before last Friday morning, according to Taiwan's defense ministry, after U.S. lawmakers met with Koo in a rare publicly disclosed meeting. On the morning of June 20, Taiwan detected a spike in Chinese movements near the island, after China criticized a British navy vessel patrolling the Taiwan Strait for the first time since 2021. 'No matter what they say or do, they cannot change the fact that Taiwan is part of China,' Chinese foreign ministry spokesperson Guo Jiakun said. China's defense ministry said on Thursday that its military drills are 'necessary to defend national sovereignty and territorial integrity, and a stern warning to 'Taiwan independence' separatists and external interference.' The ministry added that U.S. support of Taiwan could 'mislead Taiwan into the flames of war.' Qi Dongtao, a senior research fellow at the East Asian Institute at the National University of Singapore, tells TIME that Trump's approach to China makes it difficult to know whether the U.S. would militarily intervene to defend Taiwan. Former President Joe Biden moved the U.S. from 'strategic ambiguity'—the policy of deliberately not clarifying whether the U.S. would militarily defend Taiwan—to 'strategic clarity,' Qi says. On multiple occasions, including in an interview with TIME last year, Biden said he wouldn't rule out 'using military force' to defend Taiwan in the case of an invasion. But Trump has moved the U.S. position back towards uncertainty. Trump is, by and large, 'not ideologically driven,' Qi says. Rather, his approach is 'transactional.' Trump Administration officials have also demanded that Taiwan increase its defense spending to as much as 10% of its gross domestic product, as part of an overall push for the U.S.' partners to spend more on their own defenses. Alexander Gray, a senior fellow at the Atlantic Council and former chief of staff of the National Security Council during Trump's first term, told Nikkei Asia that Israel's aerial campaign was 'the ultimate example of America First regional burden sharing'—signalling that the Trump Administration expects its regional partners to do a bulk of the fighting. 'For Trump, China is mainly an economic threat,' Qi adds. For the most part, 'Trump doesn't want to fight a war with China.' World still views China as a security concern NATO Secretary-General Mark Rutte said Monday that NATO's Indo-Pacific partners—which includes Japan and South Korea—were 'very, very aware' of China's 'massive' military expansion, pointing to several Chinese defense companies that rank among the top arms makers globally. He warned that Chinese military expansion could also impact European security. 'They don't do this only because they want to have nice parades in Beijing. I guess it's there for a reason,' Rutte said. He pointed to 'the situation in Taiwan' and cautioned that should China 'try anything with Taiwan,' Beijing could rely on Russia to 'keep us busy here' in Europe. Rutte's comments signal that the West still views China mainly as a geopolitical security threat, even as Beijing tries to warm ties with Europe. 'We firmly oppose NATO using China as an excuse to expand eastward into the Asia-Pacific and urge NATO to reflect on its own behaviors, change course, and contribute more to global security and stability,' Chinese defense spokesperson Senior Colonel Zhang Xiaogang said at a regular press conference on Thursday. 'China wants to be seen as a neutral player,' Lin says. But the U.S. is still 'the dominant power in the region' and by most counts the world, whereas China is a 'relatively recent entry' diplomatically and economically to the Middle East. Even with some upgraded diplomatic ties in the Middle East, China is viewed mainly as an economic player, Lin adds. That informs China's need to balance its interests in and ties to several countries at once. If China were seen as 'too passive or too close to Iran,' for example, 'it could limit China's Belt and Road ambitions in the region.' With other nations too, China is seen as a major economic player, but taken with a grain of salt with regards to diplomacy. 'It is clear that China is one of the largest trading partners, and we have a few issues like climate change where we cooperate, but every relationship requires a dose of realism,' European Union foreign policy chief Kaja Kallas told reporters Monday after a meeting between E.U. foreign ministers. 'China is the key enabler of Russia's war against Ukraine. It carries out cyberattacks. It interferes in our democracies. It uses coercive trade practices. These aspects strain our relationship and make it increasingly hard to continue as before.' Even in the economic arena, China's relations have faltered. The E.U. earlier this month cancelled a flagship economic meeting with China over ongoing trade disputes. U.S. sanctions have spurred collaboration between China, Russia, Iran, and North Korea, including through setting up international collaborative organizations like BRICS as alternatives to a U.S.-led international order. But the global influence of these organizations is hampered by a lack of 'sufficient critical mass,' Stephen Olson, a visiting senior fellow at the ISEAS Yusof Ishak Institute, told Nikkei Asia. In another blow to China's push to become a regional leader, India on Thursday rejected signing a joint statement facilitated by the Shanghai Cooperation Organization—one such grouping set up by China and Russia to counter U.S. influence. Israel-Iran conflict was 'a stage' for U.S. and China's contrasting approaches China's continued policy of non-involvement contrasts sharply with what the world has seen from the U.S. in the past week—not to mention decades of its interventionist approach before Trump—which has allowed China to make 'great strides particularly in the Global South,' Lin tells TIME. That's intentional, Lin says, lest China lets itself become 'indistinguishable from the hegemonic powers it criticizes.' 'This conflict between Iran and Israel has somehow become a stage for China and the U.S. to showcase contrasting visions of global leadership,' Lin says. 'The U.S. has demonstrated its military capabilities, its commitment to allies, and its influence in crisis management. But these are not the metrics by which China measures its global role.' Where the U.S. wielded threats and weapons, China offered words. 'China's main stake is stability,' Lin says. 'History shows that great power involvement often worsens long-term instability. China does not aspire to become a world policeman, nor does it believe any single country should assume that role.'
Forbes
2 hours ago
- Forbes
A Compound Made From Shrimp Shells Can Rid The Body Of Microplastics
For those unaware of the extent of the problem, microplastics (MPs) are said to be in essentially every person in every part of the world. Ice samples from the poles and tissue samples from the penis show the extent of penetration. Given that these pieces of plastic have been found in placenta samples and reproductive organs, we can say that children are being subjected to plastic exposure from birth. To what degree these nano and microplastics will hurt humans is still debated and research is ongoing, and the FDA states that they'll take regulatory action when adverse effects are known. However, the reason that people prefer to avoid becoming plasticized is the conventional wisdom that having small pieces of plastic within our immune cells, nerve cells, and altering which genes are expressed is something we'd want to avoid. There's certainly no known benefit. Microplastics have ben detected basically everywhere, including the brain and penis. Recent studies discuss the 'ubiquitous' extent of microplastics and their varied effects. Kidney death, liver inflammation, oxidative stress, cellular toxicity, alterations in gene expression and changes to the DNA itself are some of the observed effects of microplastic exposure. I will hypothesize that there's potentially a link between nanoplastics and mental wellbeing. Not just from the obvious observation that plastics in the brain are bad, although this is true; I instead refer to the interference that our gastrointestinal microbiota are suffering with their extracellular vesicles because of microplastics. Understanding the brain-gut-microbe axis and the effect that our intestinal flora there have an impact on our neurological function, one may observe that altering this intestinal environment with nanoplastics can have an effect on mental wellbeing. If you do start depressed, try milk aromatherapy. It shows promise in rats depressed because of gut-brain issues. The Dentist For those of us who don't enjoy visits to the dentist, we have reasons to be validated. Different materials are used in different dental practices, but a lot of them are plastic or packaged in plastic. By the nature of installing implants that will be subjected to the wear and tear of using one's mouth in daily life, microplastics are created and ingested. Other procedures like polishing restorations, ceramic crowns, using elastics, orthodontic appliances, and so on can generate particles. Think about the plastic fibers on the plastic toothbrush you grind against your teeth twice a day. Should we go back to chewing spruce sap? Remedies Chitin is a compound found in mushrooms and the exoskeletons of crustaceans and insects. Chitosan is easily made from chitin. It's used as a dietary supplement and sold to help consumers feel full, block fat absorption and lower cholesterol. Good for wound care as well. We ought to produce more of it and make it mainstream because we have another important reason to like it. A new study has shown that it can benefit our well-being in a novel and needed way: ridding our bodies of microplastics. The study was short but revealing, and I hope it will be reproduced with longer durations and human subjects. The researchers share two important conclusions. For even short periods of ingestion, microplastics accrue in the digestive tract, primarily the cecum which is the pouch between the small intestine and colon. Assuming that chemicals can leach from these plastics and that the particles themselves will eventually absorb into the wider body, it's clearly advantageous to expel this poison before it accrues/accumulates. The group of rats that was fed a diet supplemented with chitosan expelled more MPs that any of the other groups. Intriguingly and encouragingly for me, over a few days the rats released more MPs than they took in. This suggests that chitosan won't just block absorption of current MPs, but in fact facilitate the cleansing of the colon of recently ingested microplastics. Further, after the rats were euthanized and dissected, the chitosan group had the lightest colons which suggests that they had the least total waste accumulated. As side effects for adding chitosan to one's diet are minimal beyond some stomach upset, UNLESS YOU ARE ALLERGIC TO SHELLFISH OR MUSHROOMS, it seems like a reasonable addition. This is not medical advice and as I said, I look forward to studies done with humans for longer periods to provide us with more information. With said I'm intrigued. Singapore. Green buildings trap microplastics, clean the air and water, and cool the city. Prevention A better way to go than solving a problem is to prevent it. Microplastics come from plastics, and despite some laws and public initiatives, the industry is vital and won't fade away naturally. Proactive investment in alternatives will bring about a whole society shift; personal choice is not an option here. Plastic is ubiquitous and a consumer doesn't have a real option to move away from it. Our tap water and the air we breathe are contaminated, so we must do more than avoid microwaving food in plastic containers, or stop buying items packaged in plastic. If anyone has been to any store ever, they would know that this is impossible. Everything is wrapped in plastic. To exist in the modern world is to be a creator of waste; even the well-intentioned can do little more than be frustrated. Green roofs are 97.5% effective in removing microplastics. They're generally good for retaining storm water, cleaning the air and runoff, which lessens the work of wastewater treatment plants. Green roofs can contribute to an urban cooling effect, countering the Urban Head Island (UHI) problem. Singapore has been a prime example of this for years. Now, we find another reason to widely adopt the practice in every city, immediately. Singapore exemplifies greening a city to everyone's benefit. Great Pacific Garbage Patch Removing what's already been released is a net benefit. When considering the scale of the undertaking to clean the North Pacific Garbage Patch and the greenhouse gasses that will be released or the marine life that will be interfered with, it isn't immediately clear what the best approach might be. Leaving it and hoping a reef grows on top of it could make sense, given the rubber tire reef projects we've all heard about. A comparative analysis of the Ocean Cleanup shows that while there will be some impact from action, the effect of doing nothing is significantly worse. Proactive action where possible to remove what's been released before it continues to break down into microplastics and nano plastics is a viable strategy for long term environmental health. In the scenario presented, plastic pollution levels drop to below what's considered a safe limit. Inaction has the higher cost. Leaving plastics in the oceans will be more damaging than removal. Complex problems can't be solved with simple solutions. Plastics can't be completely replaced, but we can adapt the ways we use them and consider novel strategies to mitigate their harm. When these strategies prove themselves to be effective, they ought to be systematically applied.
Yahoo
6 hours ago
- Yahoo
FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down
Gilead Sciences, Inc. GILD announced that the FDA has placed a clinical hold on studies on pipeline candidates, GS-1720 and/or GS-4182, for the treatment of HIV. GS-1720 is an investigational integrase strand transfer inhibitor and/or GS-4182 is an investigational capsid inhibitor. Shares were down 2.6% on the news. Year to date, shares of GILD have gained 20% against the industry's decline of 0.5%. Image Source: Zacks Investment Research The FDA placed a clinical hold on the studies due to the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and GS-4182. The studies that have been placed on hold are a phase II/III study evaluating the safety and efficacy of oral weekly regimen of GS-1720 in combination with GS-4182 versus Biktarvy in virologically suppressed people with HIV-1 and a phase II/III study evaluating the safety and efficacy of oral weekly regimen of GS-1720 in combination with GS-4182 versus Biktarvy in treatment-naive people with HIV-1. Three additional phase I studies of either these candidates/or their combinations are also on hold. While the clinical hold will somewhat derail the development program for these candidates, GILD is a market leader in HIV treatments. Gilead's flagship drug, Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg, BIC/FTC/TAF), for HIV-1 infection has become the leading prescribed regimen for both treatment-naïve and switch patients. Biktarvy accounts for over 51% share of the treatment market in the United States and should maintain momentum for GILD in the upcoming quarters. Descovy (FTC 200 mg/TAF 25 mg) for pre-exposure prophylaxis (PrEP) is also witnessing good uptake. It maintains over 40% market share in the PrEP market in the United States. Gilead's efforts to innovate its HIV portfolio are impressive. Late-stage studies, PURPOSE 1 and PURPOSE 2, validated lenacapavir's potential to prevent HIV. The FDA accepted new drug application submissions for twice-yearly lenacapavir for HIV prevention under priority review, with a target action date of June 19, 2025. Gilead Sciences, Inc. price-consensus-eps-surprise-chart | Gilead Sciences, Inc. Quote The European Medicines Agency validated the Marketing Authorization Application and EU-Medicines for All application for twice-yearly lenacapavir for HIV prevention. The successful development and potential approval of lenacapavir for the prevention of the disease should solidify Gilead's HIV franchise. Per GILD, lenacapavir, with its twice-yearly dosing, could set a new bar for HIV prevention and allow PrEP to reach out to a larger number of people who could benefit from a prevention regimen. However, Biktarvy sales are expected to be under pressure due to Medicare Part D redesign, which, in turn, should affect overall HIV growth. Gilead's faces stiff competition from GSK plc GSK in the HIV space. GSK's HIV portfolio sales are being driven by strong patient demand for Cabenuva, Apretude and Dovato. The company is also focused on the development of the next generation of HIV innovation with integrase inhibitors (INSTIs) for HIV treatment and prevention. Gilead currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the pharma/biotech sector are Novartis NVS and Bayer BAYRY, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate Novartis' 2025 earnings per share (EPS) has risen from $8.46 to $8.74 over the past 60 days. EPS estimates for 2026 have jumped 35 cents to $9.02 during this timeframe. The stock has risen 24.7% so far this year. BAYRY's 2025 EPS estimate has increased from $1.19 to $1.25 for 2025 over the past 60 days, while that for 2026 has gone up from $1.28 to $1.31 over the same timeframe. Year to date, shares of Bayer have surged 56.7%. BAYRY's earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
